Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Q4 2024 value amounting to $1.9 million.

  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures rose 1336.5% to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year increase of 1336.5%. This contributed to the annual value of $1.9 million for FY2024, which is 1336.5% up from last year.
  • According to the latest figures from Q4 2024, Ironwood Pharmaceuticals' Gains from Sales and Divestitures is $1.9 million, which was up 1336.5% from $1.7 million recorded in Q4 2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $1.9 million in Q4 2024 and a low of $965625.0 during Q4 2020
  • Its 5-year average for Gains from Sales and Divestitures is $1.5 million, with a median of $1.7 million in 2023.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Gains from Sales and Divestitures crashed by 2563.74% in 2020, and later soared by 7581.83% in 2021.
  • Over the past 5 years, Ironwood Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $965625.0 in 2020, then surged by 75.82% to $1.7 million in 2021, then decreased by 21.8% to $1.3 million in 2022, then rose by 25.34% to $1.7 million in 2023, then increased by 13.36% to $1.9 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.9 million for Q4 2024, versus $1.7 million for Q4 2023 and $1.3 million for Q4 2022.